FI118886B - Användning av en kombination av ett ytaktivitetsmedel för lungorna och minst en glukokortikosteroid för framställning av ett läkemedel avsett för vård av IRDS och ARDS - Google Patents

Användning av en kombination av ett ytaktivitetsmedel för lungorna och minst en glukokortikosteroid för framställning av ett läkemedel avsett för vård av IRDS och ARDS Download PDF

Info

Publication number
FI118886B
FI118886B FI971277A FI971277A FI118886B FI 118886 B FI118886 B FI 118886B FI 971277 A FI971277 A FI 971277A FI 971277 A FI971277 A FI 971277A FI 118886 B FI118886 B FI 118886B
Authority
FI
Finland
Prior art keywords
treatment
combination
use according
ards
irds
Prior art date
Application number
FI971277A
Other languages
English (en)
Finnish (fi)
Other versions
FI971277A (sv
FI971277A0 (sv
Inventor
Klaus Eistetter
Ulrich Kilian
Dietrich Haefner
Paul-Georg Germann
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of FI971277A0 publication Critical patent/FI971277A0/sv
Publication of FI971277A publication Critical patent/FI971277A/sv
Application granted granted Critical
Publication of FI118886B publication Critical patent/FI118886B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Claims (9)

1. Användning av en kombination av ett ytaktivi-tetsmedel för lungorna och minst en glukokortikosteroid 5 för framställning av ett läkemedel avsett för värd av IRDS och ARDS.
2. Användning enligt patentkrav 1, känneteck-nad av att kombinationen innehäller som glukokortikoste-roider betametason, budesonid, metylprednisolon, dexameta- 10 son och/eller siklesonid.
3. Användning enligt patentkrav 1, känneteck-nad av att kombinationen innehäller som ytaktivitetsme-del för lungorna en blandning av fosfolipider.
4. Användning enligt patentkrav 3, känneteck-15 nad av att kombinationen innehäller fosfolipider som fö- rekommer i naturliga ytaktivitetsmedel för lungorna.
5. Användning enligt patentkrav 3, känneteck-n a d av att kombinationen dessutom innehäller ytaktivi-tetsmedel-proteiner för lungorna.
6. Användning enligt patentkrav 5, känneteck- nad av att kombinationen innehäller SP-B och/eller SP-C ·· i ’·· och/eller varianter av dessa. ·· • 1·.
7. Användning enligt patentkrav 4, känneteck- nad av att kombinationen innehäller genom lungsköljning ····· 25 tillvaratagna ytaktivi tetsmedel för lungorna. ϊ1.
8. Användning enligt patentkrav 1, känneteck- • nad av att läkemedlet är i pulverform för administrering • » · som sker i form av inhalation.
, . 9. Användning enligt patentkrav 1, känneteck- • · · 30 nad av att läkemedlet är i vätskeform för luftstrups- • 1 *«·1 eller luftrörsinvändig administrering. • · • · · • M · ··· • t • « ··· ·· · • · · • · • « «
FI971277A 1994-09-28 1997-03-26 Användning av en kombination av ett ytaktivitetsmedel för lungorna och minst en glukokortikosteroid för framställning av ett läkemedel avsett för vård av IRDS och ARDS FI118886B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4434629 1994-09-28
DE4434629A DE4434629C1 (de) 1994-09-28 1994-09-28 Zusammensetzungen zur Behandlung von IRDS und ARDS
EP9503816 1995-09-27
PCT/EP1995/003816 WO1996009831A2 (de) 1994-09-28 1995-09-27 Zusammensetzungen zur behandlung von irds und ards, die mindestens ein glucocorticosteroid in kombination mit einem lungen surfactant enthalten

Publications (3)

Publication Number Publication Date
FI971277A0 FI971277A0 (sv) 1997-03-26
FI971277A FI971277A (sv) 1997-05-27
FI118886B true FI118886B (sv) 2008-04-30

Family

ID=6529394

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971277A FI118886B (sv) 1994-09-28 1997-03-26 Användning av en kombination av ett ytaktivitetsmedel för lungorna och minst en glukokortikosteroid för framställning av ett läkemedel avsett för vård av IRDS och ARDS

Country Status (26)

Country Link
US (1) US5891844A (sv)
EP (1) EP0783314B1 (sv)
JP (1) JP4425991B2 (sv)
KR (1) KR100365030B1 (sv)
CN (1) CN1100542C (sv)
AT (1) ATE241372T1 (sv)
AU (1) AU705099B2 (sv)
BG (1) BG62556B1 (sv)
CA (1) CA2201377C (sv)
CZ (1) CZ292846B6 (sv)
DE (2) DE4434629C1 (sv)
DK (1) DK0783314T3 (sv)
EE (1) EE03422B1 (sv)
ES (1) ES2201120T3 (sv)
FI (1) FI118886B (sv)
HK (1) HK1003869A1 (sv)
HU (1) HU226958B1 (sv)
MX (1) MX9702303A (sv)
NO (1) NO313405B1 (sv)
NZ (1) NZ294587A (sv)
PL (1) PL187496B1 (sv)
PT (1) PT783314E (sv)
RU (1) RU2157222C2 (sv)
SK (1) SK284446B6 (sv)
UA (1) UA43378C2 (sv)
WO (1) WO1996009831A2 (sv)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
IL130658A (en) * 1997-02-17 2004-07-25 Altana Pharma Ag Preparations for the treatment of ARDS or IRDS containing 3 - (cyclopropylmethoxy) - N - (3, 5 - dichloro - 4 - pyridinyl) - 4 - (difluoromethoxy) benzamide and solvent for the lungs
US20060281681A1 (en) 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
US7122344B2 (en) 1997-05-28 2006-10-17 Claragen, Inc. Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
CN1194833A (zh) * 1997-10-08 1998-10-07 刘柏宏 肺活素
US6858223B2 (en) 1998-06-23 2005-02-22 Altana Pharma Ag Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS)
EP1189625A1 (en) * 1999-06-11 2002-03-27 Byk Gulden Lomberg Chemische Fabrik GmbH Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c)
AU6083899A (en) * 1999-09-16 2001-04-17 Aventis Behring Gmbh Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
DE19957898A1 (de) * 1999-12-01 2001-06-07 Byk Gulden Lomberg Chem Fab Neue Verwendung von Lungensurfactant
SI1276495T1 (sl) * 2000-04-12 2006-10-31 Altana Pharma Ag Uporaba rekombinantnega pljucnega surfaktanta za zgodnje zdravljenje akutnih pljucnih bolezni
US20040254112A1 (en) * 2000-04-12 2004-12-16 Dietrich Hafner Use of pulmonary surfactant for the early treatment of acute pulmonary diseases
DE10018022A1 (de) * 2000-04-12 2001-10-31 Byk Gulden Lomberg Chem Fab Neue Verwendung von Lungensurfactant zur Prophylaxe oder Frühbehandlung von akuten Lungenerkrankungen
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
MXPA02001323A (es) * 2000-05-10 2004-07-16 Alliance Pharma Microgranulos con base fosfolipida para la liberacion de farmaco.
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
US20030099601A1 (en) * 2001-11-27 2003-05-29 Gordon Marc S. Inhalation lung surfactant therapy
WO2003053455A1 (en) * 2001-12-12 2003-07-03 Penn State Research Foundation Surfactant prevention of lung complications from cancer chemotherapy
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
US7238664B2 (en) 2003-06-16 2007-07-03 Altana Pharma Ag Composition comprising a pulmonary surfactant and a PDE5 inhibitor for the treatment of lung diseases
PT1670482E (pt) * 2003-09-16 2014-03-12 Takeda Gmbh Utilização de ciclesonida para o tratamento de doenças respiratórias
US7582312B2 (en) * 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US7464012B2 (en) * 2004-12-10 2008-12-09 L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude Simplified process simulator
PL1841458T3 (pl) 2005-01-06 2012-05-31 Discovery Lab Inc Schemat stosowania środka powierzchniowo czynnego do leczenia lub zapobiegania dysplazji oskrzelowo-płucnej
KR100891595B1 (ko) 2005-02-28 2009-04-03 주식회사 케이티앤지 혈액 단백질의 삼출을 감소시키는 조성물
AU2007297691B2 (en) * 2006-09-19 2013-12-19 Discovery Laboratories, Inc. Pulmonary surfactant formulations and methods for promoting mucus clearance
EP2022798A1 (en) * 2007-08-09 2009-02-11 CHIESI FARMACEUTICI S.p.A. Synthetic pulmonary surfactant peptides
WO2012077127A1 (en) * 2010-12-10 2012-06-14 Indian Institute Of Technology, Bombay A protein free surfactant composition for pulmonary diseases and a process for preparing the same
WO2013188016A2 (en) 2012-05-04 2013-12-19 Discovery Laboratories, Inc. Surfactant therapy for exposure to ionizing radiation
CN106310280A (zh) * 2016-08-18 2017-01-11 滨州医学院 地瑞那韦增强糖皮质激素抗炎作用的医药新用途
CN110099695B (zh) * 2016-12-22 2022-01-25 奇斯药制品公司 用于治疗进展性bpd的包含肺表面活性物质和类固醇的治疗组合

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4944941A (en) * 1987-08-07 1990-07-31 Genentech, Inc. Methods and compositions for the treatment of lung conditions
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances

Also Published As

Publication number Publication date
BG62556B1 (bg) 2000-02-29
HUT77931A (hu) 1998-11-30
SK284446B6 (sk) 2005-04-01
NZ294587A (en) 1998-07-28
CN1100542C (zh) 2003-02-05
FI971277A (sv) 1997-05-27
US5891844A (en) 1999-04-06
CN1163571A (zh) 1997-10-29
BG101441A (en) 1997-09-30
FI971277A0 (sv) 1997-03-26
KR970706006A (ko) 1997-11-03
SK40197A3 (en) 1998-02-04
HK1003869A1 (en) 1998-11-13
DE4434629C1 (de) 1996-06-27
RU2157222C2 (ru) 2000-10-10
AU705099B2 (en) 1999-05-13
KR100365030B1 (ko) 2003-03-10
PL187496B1 (pl) 2004-07-30
JP4425991B2 (ja) 2010-03-03
CA2201377A1 (en) 1996-04-04
CZ292846B6 (cs) 2003-12-17
JPH10506119A (ja) 1998-06-16
PT783314E (pt) 2003-10-31
EE9700084A (et) 1997-10-15
ATE241372T1 (de) 2003-06-15
CZ94097A3 (en) 1997-09-17
WO1996009831A3 (de) 1996-05-23
HU226958B1 (en) 2010-03-29
PL319608A1 (en) 1997-08-18
WO1996009831A2 (de) 1996-04-04
UA43378C2 (uk) 2001-12-17
EE03422B1 (et) 2001-06-15
DE59510705D1 (de) 2003-07-03
NO971403L (no) 1997-04-17
CA2201377C (en) 2008-07-29
NO313405B1 (no) 2002-09-30
AU3742895A (en) 1996-04-19
NO971403D0 (no) 1997-03-25
DK0783314T3 (da) 2003-12-01
EP0783314B1 (de) 2003-05-28
ES2201120T3 (es) 2004-03-16
MX9702303A (es) 1997-06-28
EP0783314A2 (de) 1997-07-16

Similar Documents

Publication Publication Date Title
FI118886B (sv) Användning av en kombination av ett ytaktivitetsmedel för lungorna och minst en glukokortikosteroid för framställning av ett läkemedel avsett för vård av IRDS och ARDS
JP5666569B2 (ja) サーファクタントタンパク質ｂ（ｓｐ−ｂ）およびサーファクタントタンパク質ｃ（ｓｐ−ｃ）の類似体を含有する改善された再構築サーファクタント組成物
MXPA97002303A (en) Compositions containing at least one glucocorticoid in combination with a pulmonary surgical agent for the treatment of child respiratory suffering syndrome and respiratory suffering syndrome ag
EP1833503B1 (en) Pulmonary surfactant formulations
KR101516443B1 (ko) 개선된 특성을 가지는 재구성된 계면활성제
KR102122088B1 (ko) 재구성된 폐 계면활성제
EP1216052A1 (en) Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
EP1480667B1 (en) Compositions comprising pulmonary surfactants and a polymyxin having improved surface properties
JP4767854B2 (ja) 合成界面活性剤のための新規な脂質混合物
KR101721309B1 (ko) 계면활성 단백질 ｂ(ｓｐ－ｂ) 및 계면활성 단백질 ｃ(ｓｐ－ｃ)의 유사체를 포함하는 합성 폐 계면활성제 조성물
KR20190039933A (ko) 재구성된 폐 계면활성제 조성물을 포함하는 안정한 약제학적 제제

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: NYCOMED GMBH

Free format text: NYCOMED GMBH

FG Patent granted

Ref document number: 118886

Country of ref document: FI

PC Transfer of assignment of patent

Owner name: TAKEDA GMBH

MM Patent lapsed